ROCHE EXPECTS TEGISON INTRODUCTION IN 1986; ROFERON-A, RIMADYL APPROVALS ARE ALSO LIKELY; VALIUM SURPASSES 1985 SALES EXPECTATIONS TOPPING $300 MIL.